guidelines for the management of osteoporosis in women with breast cancer. It also examines the evidence about the use of bisphosphonates or denosumab in an adjuvant setting in women with early breast cancer.
Breast cancer remains the most frequent cancer in women and its incidence is increasing. However, the mortality rate has stabilized due to progress in treatment. In premenopausal women with hormone receptor-positive breast cancer, the goal of adjuvant treatment is to inhibit the impact of ---
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